Cogent Biosciences, Inc.
bezuclastinib
GIST who have received prior treatment with imatinib
Resolved
187days ago
Advisory committee · Jan 1, 2026
What's at stake
An FDA advisory committee reviews bezuclastinib for GIST who have received prior treatment with imatinib around Jan 1, 2026. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 8-K
verified 15h ago
“In January 2026, announced that the U. S. Food and Drug Administration (FDA) agreed to accept the PEAK NDA for bezuclastinib in patients with Gastrointestinal Stromal Tumors (GIST) who have received prior treatment with imatinib under the R”